Current and emerging therapies for Friedrich’s Ataxia (FA) focus on reversing the deleterious effects of such deficiency including mitochondrial augmentation and increasing frataxin levels, providing the possibility of treatment options for this physiologically complex, multisystem disorder. In this review article, the authors discuss the current and prior in vivo and...
Dear reader! So, how is it going this week? Me, more than well: Boston lost (NHL) in the Stanley Cup final – niark, niark! I … No, but no kidding, that cumulated with the victory of the Toronto Raptors (NBA) stamped a smile on face for a few days. :...
Hi reader! So, how are you doing this week? I buried the hatchet with my Ataxia. I find it hard to imagine that anyone could have pity on me; I know how to take advantage of the little that I have. I am as happy as anyone, or more, after...
Dear reader! So, what’s new these days? For my part, I’m waiting for news from my editor, patiently, about the publication of the manuscript that I sent him some time ago! If you are nice, maybe I’ll talked about this new in my next blog. In the meantime, I’m going...
Useful links for tax time! We took some time to prepare reference links for the tax period. There are changes every year on tax rules and it is important for you to check if this can affect you! A tax credit is used to reduce the tax payable by the...
Neurocrine Biosciences and Voyager Therapeutic announced the formation of a strategic collaboration focused on the development and commercialization of Voyager’s gene therapy programs, VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences’ expertise in neuroscience,...